文献速递医学人工智能与信息学临床试验与 GCP流行病学与生物统计

数字临床决策支持算法指导卢旺达儿科门诊抗生素处方的效果:一项实用整群非随机对照试验

Effectiveness of a digital clinical decision support algorithm for guiding antibiotic prescribing in pediatric outpatient care in Rwanda: A pragmatic cluster non-randomized controlled trial.
PubMed 文献 · PLoS Med · 2026-02-26

在卢旺达32家健康中心开展实用整群非随机对照试验,评估ePOCT+数字算法对≤14岁急性病患儿抗生素处方的影响。干预后抗生素处方率从70.5%降至24.5%,临床失败率非劣,但干预组转诊和住院率较高,可能源于基线病情差异。

要点

  • ePOCT+算法使抗生素处方率绝对下降46.0%(95%CI -52.5至-39.5)。
  • 临床失败率非劣:aRR 1.07(95%CI 0.97-1.18)。
  • 干预组转诊和住院率较高,但前后对照无差异,提示基线病情差异。

核心结论

  • ePOCT+在卢旺达儿科初级保健中大幅减少抗生素处方,且不损害临床恢复。

研究设计与样本

  • 实用、开放标签、整群非随机对照试验,32家健康中心按地理分配,平衡患者量和基础设施。
  • 16家站点全程使用ePOCT+,另16家先提供标准治疗5个月后交叉。
  • 纳入59921次咨询,分析47822次新咨询;采用混合效应逻辑回归调整年龄、性别、地区及主诉。

主要发现

  • 符合方案分析中,干预-对照比较抗生素处方从70.5%降至24.5%(绝对差-46.0,95%CI -52.5至-39.5)。
  • 前后对照比较处方降至27.5%(绝对差-43.0,95%CI -49.7至-36.4)。
  • 意向治疗敏感性分析干预-对照绝对差-36.7(95%CI -42.1至-31.3),前后对照-26.7(95%CI -32.2至-21.4)。
  • 临床失败率非劣:干预-对照aRR 1.07(95%CI 0.97-1.18),前后对照aRR 1.00(95%CI 0.92-1.10)。
  • 干预-对照比较中,转诊率aRR 2.11(95%CI 1.20-3.70)、原发性住院aRR 2.02(95%CI 1.21-3.38)、继发性住院aRR 1.93(95%CI 1.17-3.16)、严重结局aRR 1.88(95%CI 1.11-3.15)在干预组更高,但前后对照无差异。

关键数值与推荐

  • 主要结局抗生素处方的优效性定义为较常规护理降低≥25%。
  • 临床失败(主要次要结局)的非劣效性定义为调整风险比上限95%CI <1.3。
  • ePOCT+整合了氧饱和度、血红蛋白测量和C反应蛋白检测。

临床怎么用

  • ePOCT+可用于儿科初级保健以减少抗生素过度处方,但需关注转诊和住院率变化。
  • 建议将ePOCT+整合入卢旺达国家电子病历平台以统一临床和报告功能。

局限性

  • 非随机设计。
  • 结局为自我报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poor adherence to clinical guidelines and diagnostic uncertainty are key contributors to antibiotic overprescription, accelerating antimicrobial resistance. We developed ePOCT+, a digital clinical decision support algorithm (previously published) that integrated oxygen saturation, hemoglobin measurements, and C-reactive protein testing to assist primary care clinicians in managing acutely ill children aged 14 years or below. The goal was to reduce antibiotic prescriptions without compromising clinical recovery. METHODS AND FINDINGS: We conducted a pragmatic, open-label cluster non-randomized controlled trial in 32 Rwandan health centers allocated to two groups by geography, balancing patient volume and infrastructure. Sixteen sites used ePOCT+ throughout; the other 16 provided standard care for five months before crossing over. This design supported three comparisons: intervention-control (months 1-5), before-after (control sites pre- versus post-crossover), and longitudinal assessment (intervention sites over 10 months). ePOCT+ was deployed in a digital application; the same application (without the algorithm) served as an electronic case report form in the control arm. Outcomes were analyzed using mixed-effects logistic regression, adjusted for age, sex, district, and presenting complaints. Superiority in antibiotic prescription (primary outcome) was defined as ≥25% reduction versus routine care. Non-inferiority for clinical failure (main secondary outcome) was defined as adjusted risk ratio upper 95% CI <1.3. Several other secondary outcomes were analyzed and reported. Between December 2021 and April 2023, 59,921 consultations were enrolled and 47,822 new consultations were analyzed. ePOCT+ uptake averaged 70% across all intervention periods. In the primary per-protocol analysis, antibiotic prescriptions declined from 70.5% to 24.5% in the intervention-control comparison (absolute difference -46.0, 95% CI [-52.5, -39.5]) and to 27.5% in the before-after comparison (absolute difference -43.0, 95% CI [-49.7, -36.4]). Reductions in the intention-to-treat sensitivity analysis were -36.7 (95% CI [-42.1, -31.3]) in the intervention-control comparison and -26.7 (95% CI [-32.2, -21.4]) in the before-after comparison, respectively. Prescription rates remained low (25%-40%) throughout the longitudinal assessment. Clinical failure rates were non-inferior (per-protocol aRR 1.07, 95% CI [0.97, 1.18] and 1.00, 95% CI [0.92, 1.10] in intervention-control and before-after analyses, respectively). In the intervention-control comparison, referral rates (aRR 2.11, 95% CI [1.20, 3.70]), primary hospitalizations (aRR 2.02, 95% CI [1.21, 3.38]), secondary hospitalizations (aRR 1.93, 95% CI [1.17, 3.16]), and severe outcomes (comprised primarily of non-referred secondary hospitalizations; aRR 1.88, 95% CI [1.11, 3.15]) were higher in the intervention arm; no differences were observed in the before-after comparison, suggesting possible baseline differences in patient severity rather than intervention effects. Re-attendance rates did not differ between arms. Malaria testing among febrile cases improved (aRR 1.27, 95% CI [1.08, 1.41]), while treatment adherence remained high. Study limitations included non-randomized design and self-reported outcomes. CONCLUSIONS: ePOCT+ substantially reduced antibiotic prescribing in Rwandan pediatric primary care without compromising clinical recovery. Integration into Rwanda's national electronic medical record platform is critical to ensure unified clinical and reporting functions. This could streamline service delivery, improve data quality, and promote evidence-based care at scale. TRIAL REGISTRATION: Clinicaltrials.gov NCT05108831.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Kulinkina AV, Rwandarwacu VP, Habakurama J, et al. Effectiveness of a digital clinical decision support algorithm for guiding antibiotic prescribing in pediatric outpatient care in Rwanda: A pragmatic cluster non-randomized controlled trial. PLoS Med. 2026. PMID: 41746877. doi:10.1371/journal.pmed.1004692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。